Clinical Trials
Helus Pharma to Present at Jefferies Global Healthcare Conference Amid Key Clinical Milestones
Helus Pharma, a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions, will participate in a fireside chat at the Jefferies Global Healthcare Conference, highlighting its Phase 3 and Phase 2 programs for major depressive disorder and generalized anxiety disorder.
Regentis Biomaterials Advances Toward Key Milestones for Simplified Cartilage Repair Platform
Regentis Biomaterials Ltd. is progressing its GelrinC hydrogel implant toward European commercialization and U.S. FDA submission, targeting a $3 billion market for knee cartilage repair with a cell-free, single-step procedure.
Optimi Health Welcomes Australia's TGA Framework Update, Expanding Psychedelic Therapy Access
Optimi Health Corp. highlights Australia's updated TGA framework for psilocybin and MDMA, which broadens therapy teams and treatment settings, potentially accelerating adoption of psychedelic-assisted therapy.
Regentis Biomaterials Targets $3 Billion Knee Cartilage Repair Market with Off-the-Shelf GelrinC Platform
Regentis Biomaterials’ GelrinC platform shows promise as a first-in-class, off-the-shelf solution for knee cartilage repair, with clinical data indicating approximately 100% greater pain improvement versus microfracture and a clear path to U.S. market entry.
Quantum BioPharma Advances Multiple Sclerosis Program with Differentiated Approach
Quantum BioPharma is progressing its clinical-stage multiple sclerosis program targeting demyelination, a novel strategy distinct from immune-modulating therapies, while maintaining a diversified portfolio including consumer wellness products and sufficient capital through 2028.
Jupiter Neurosciences Raises $2 Million in Registered Direct Offering
Jupiter Neurosciences closes a $2 million registered direct offering to fund its clinical programs targeting CNS disorders and neuroinflammation.
Onco-Innovations Advances Manufacturing Scale-Up for Lead Cancer Drug Candidate ONC010
Onco-Innovations Limited reports progress in intermediate-scale manufacturing for its nanoparticle-formulated oncology candidate ONC010, moving it closer to clinical trials in Australia.
Regentis Biomaterials Targets Knee Cartilage Repair Market with Off-the-Shelf Hydrogel Implant
Regentis Biomaterials advances GelrinC, a cell-free hydrogel implant for knee cartilage repair, as clinical trials progress and a new manufacturing process scales production.
TransCode Therapeutics Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease
TransCode Therapeutics has started a Phase 2a trial evaluating TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduce recurrence risk in a high-risk population.
Tonix Pharmaceuticals Publishes Phase 1 TNX-1500 Data, Paving Way for Kidney Transplant Study
Tonix Pharmaceuticals announced publication of Phase 1 data for TNX-1500, an anti-CD40L monoclonal antibody, showing favorable safety and pharmacodynamics, supporting advancement to a Phase 2 kidney transplant rejection study.
VolitionRx Reports Progress in Diagnostics Pipeline, Including Feline Lymphoma Manuscript Submission Tied to $5M Milestone
VolitionRx provided a corporate update highlighting clinical and commercial progress, including a feline lymphoma manuscript submission linked to a $5 million milestone payment and licensing discussions with over a dozen global diagnostic companies.
Regentis Biomaterials Targets $3 Billion U.S. Knee Cartilage Repair Market with GelrinC
Regentis Biomaterials’ GelrinC offers a potential first-in-class, off-the-shelf solution for knee cartilage repair, with Phase III trial underway and CE Mark approval in Europe.
Regentis Biomaterials Advances GelrinC as Off-the-Shelf Solution for Knee Cartilage Repair, Targeting a 472,500-Procedure Gap
Regentis Biomaterials is developing GelrinC, a cell-free hydrogel implant for knee cartilage repair, which could fill a market gap as no approved off-the-shelf regenerative solution exists in the U.S., with a pivotal FDA trial now over 50% enrolled and a new manufacturing process boosting yield by 400%.
SureNano Science Targets Obesity Market with Novel GLP-1 Therapy GEP-44
SureNano Science Ltd. is advancing a differentiated GLP-1-based therapy, GEP-44, aiming to compete in the rapidly growing obesity and metabolic disease market dominated by blockbusters like Ozempic and Wegovy.
Telomir Pharmaceuticals Reports Preclinical Data Showing Telomir-Zn Benefits in Wilson’s Disease Model
Telomir Pharmaceuticals announced peer-reviewed preclinical data demonstrating that Telomir-Zn improved survival and reduced oxidative stress and copper burden in a Wilson’s disease model, expanding the drug’s potential beyond its lead cancer program.
Annovis Bio Announces Public Offering to Fund Buntanetap Alzheimer's Trial
Annovis Bio has proposed a public offering of common stock and warrants to raise capital for its Phase 3 Alzheimer's study and general corporate purposes.
Annovis Bio Raises $15 Million in Public Offering to Fund Neurodegenerative Disease Trials
Annovis Bio has priced a $15 million public offering of common stock and warrants, with proceeds earmarked for clinical development of its lead candidate buntanetap for Alzheimer's and Parkinson's diseases.
Quantum BioPharma Hits Midpoint Enrollment in MS Imaging Study, Signaling Potential for Novel Diagnostic and Therapeutic Advances
Quantum BioPharma announced that its collaborative MS imaging study with Massachusetts General Hospital has reached midpoint enrollment, with preliminary PET tracer data showing promise for detecting active and gray matter lesions, which could accelerate development of its investigational MS therapy Lucid-MS.
Oragenics to Present at Sidoti Micro-Cap Virtual Investor Conference Amid Progress in Neurological Therapeutics
Oragenics Inc. will present at the Sidoti Micro-Cap Virtual Investor Conference, highlighting its intranasal delivery platform and upcoming clinical trials for concussion treatment.
Lantern Pharma Gains FDA Support for HARMONIC Trial Amendments in Never-Smoker Lung Cancer
Lantern Pharma announced FDA no objections to protocol amendments for its Phase 2 HARMONIC trial of LP-300 in never-smokers with advanced NSCLC, focusing on a specific EGFR mutation subgroup.
NanoViricides Raises $2 Million in Registered Direct Offering to Advance Antiviral Drug Pipeline
NanoViricides closes a $2 million registered direct offering with an institutional investor, providing capital to advance its broad-spectrum antiviral drug NV-387 into Phase II trials.
Oragenics Advances Phase IIa Concussion Trial, Eyes CNS Device Licensing
Oragenics provided a shareholder update on its Phase IIa trial of ONP-002 for concussion in Australia, plans for U.S. regulatory meetings, and a letter of intent to license a complementary CNS medical device.
Quantum BioPharma Reaches Midpoint Enrollment in MS Imaging Study, Showing Encouraging Early Data
Quantum BioPharma announced that patient enrollment in its multiple sclerosis imaging study with Massachusetts General Hospital has reached 50%, with preliminary PET imaging data showing promising signals in acute MS lesions and potential sensitivity to gray matter lesions, which could accelerate development of MS therapies including its candidate Lucid-MS.
Lantern Pharma Reports Q1 2026 Results: 47% R&D Cost Reduction and AI Platform Commercialization
Lantern Pharma's Q1 2026 results show a 47% year-over-year reduction in R&D spending, successful FDA milestones, and the launch of withZeta.ai, a commercial AI drug development platform that opens a new revenue stream and extends cash runway into 2027.
LIXTE Biotechnology Advances LB-100 Pipeline and Expands Proton Therapy Operations
LIXTE Biotechnology reports first-quarter progress with its lead cancer drug LB-100 moving into expanded ovarian cancer trials and growth at its Liora Technologies subsidiary, signaling strategic expansion in oncology.
Annovis Bio Achieves 85% Enrollment in Phase 3 Alzheimer’s Trial, Advances Parkinson’s Program
Annovis Bio reports first-quarter progress with 85% enrollment in its pivotal Phase 3 Alzheimer's trial and 40% enrollment in its Parkinson's open-label study, signaling potential regulatory milestones for buntanetap.
NanoViricides Advances Broad-Spectrum Antiviral NV-387 Toward Phase II Trials for MPox in DRC
NanoViricides' quarterly report details progress with NV-387, including regulatory approval for Phase II MPox trials in the DRC and FDA orphan drug designation for measles, highlighting its broad-spectrum antiviral strategy.
GeoVax Advances GEO-MVA Phase 3 Trial as Mpox Vaccine Supply Concerns Persist
GeoVax reports first quarter 2026 financial results and details plans for a pivotal Phase 3 immunobridging study of its MVA-based mpox/smallpox vaccine, highlighting the strategic importance of diversifying orthopoxvirus vaccine supply amid global supply constraints.
Dogwood Therapeutics Advances Non-Opioid Pain Pipeline with Phase 2b Data Expected This Fall
Dogwood Therapeutics reported first quarter 2026 financial results, highlighting progress in its non-opioid pain treatments Halneuron and SP16, with key clinical milestones expected in 2026.
Testosterone Levels Linked to Glioblastoma Survival in Men, NIH-Funded Study Finds
A new NIH-funded preclinical study reveals that men with higher testosterone levels may have longer survival when diagnosed with glioblastoma, opening potential implications for treatments and companies like CNS Pharmaceuticals.